As measles cases in the U.S. surge to a 35-year high due to declining vaccination rates, biotech firms and academic groups are beginning to develop new treatments for infected individuals and vulnerable populations. However, these therapies may take years to become available, and it remains uncertain whether unvaccinated individuals would accept them.
Background
Measles is highly contagious and requires near-universal vaccination (95%) to achieve herd immunity; recent outbreaks highlight gaps in vaccine coverage, especially among children. Currently, no specific antiviral treatment exists—care is supportive only.
- Source
- Ars Technica
- Published
- Jul 28, 2026 at 09:32 PM
- Score
- 6.0 / 10